ABL Europe acquires Transgene's production asset

4 February 2016

US contract research and manufacturing organization ABL Inc, through its wholly-owned subsidiary ABL Europe, has acquired Transgene’s (Euronext: TNG) production asset situated in Illkirch, near Strasbourg, France. Transgene, ABL Inc and ABL Europe are all three members of the Institut Mérieux.

Financial terms of the transaction were not revealed but the news pushed up the share price of Paris traded Transgene by 2.5% to 3.29 euros in early trading. The production asset is designed and equipped to manufacture clinical lots of biopharmaceuticals and vaccines using viral vectors.

ABL Europe has just received authorization by the French Agence Nationale de Sécurité du Médicament to operate a Pharmaceutical Establishment, a mandatory step to begin operations at the site. Manufacturing and other services will be provided under European Union and US Good Manufacturing Practice (GMP).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK